Will GlaxoSmithKline plc Split Itself In Two?

GlaxoSmithKline plc (LON: GSK) is weighing up a split.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline’s (LSE: GSK) (NYSE: GSK.US) management is working hard to overhaul the FTSE 100’s largest listed pharmaceutical company, after a wave of bad news last year.   

In management’s latest attempt to create shareholder value, Glaxo’s chief executive has revealed that he is considering breaking the group up.  

Creating valuegsk

These comments from Glaxo’s management come after the pharmaceutical company unveiled a disastrous set of second-quarter results last week.

Specifically, the group reported that second quarter core operating profit plummeted 25%, or 14% on a constant exchange rate basis. Turnover fell 13%, or 4% at constant exchange rates, while core earnings per share fell 25% to 19.1p.

Unfortunately, these poor results have only compounded Glaxo’s troubles as the company tries to navigate bribery allegations. What’s more, the company is facing allegations of malpractice by employees all over the world.

Nevertheless, Glaxo’s management believes that one of the group’s most valuable assets is its consumer healthcare business. However, while Glaxo as a group is facing a storm of international criticism, investors are placing a low valuation on the company as a whole, disregarding the strengths of the consumer business.

As a result, Glaxo’s management has stated that in the future, the consumer healthcare business could be spun off, if a time came when it offered more value as a standalone company.

World leader

Thanks to its $20bn deal with Novartis earlier this year, Glaxo is set to become one of the world’s leading consumer healthcare players. Part of the deal was the creation of a consumer healthcare joint venture, with annual sales of $10bn.

Glaxo will own around 64% of the joint venture, with an option to buy out the remainder after three years.

This is where Glaxo’s management believes that value can be unlocked for shareholders. However, for the time being the consumer business fits well into the group. A spin-off right now would lead to higher costs and lower margins.

Still, the prospect of a spin-off is encouraging, especially if it creates value for shareholders.

Cash return

Glaxo’s deal with Novartis did more than create a consumer health giant. As part of the deal, Glaxo is set to receive a cash payout of £4bn, which management has promised to return to investors next year. The cash return will come as a one-off payout via a B share scheme of approximately 80p per share.

For investors, this is great news. Indeed, the one-off payout, combined with Glaxo’s current yield of 5.3%, implies that investors are in line to receive a yield of around 10% next year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »